Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2004; 25(01): 21-25
DOI: 10.1055/s-0041-1733059
Original Article

Chemotherapy for Advanced Epithelial Ovarian Cancer

LALIT KUMAR
Department of Medical Oncology, Institute Rotary Cancer Hospital. All India Institute of Medical Sciences, New Delhi-110029, India
,
DEEPA JANGA
Department of Medical Oncology, Institute Rotary Cancer Hospital. All India Institute of Medical Sciences, New Delhi-110029, India
,
SUCHITRA BERGE
Department of Medical Oncology, Institute Rotary Cancer Hospital. All India Institute of Medical Sciences, New Delhi-110029, India
,
ROOPA KEKKAR
Department of Medical Oncology, Institute Rotary Cancer Hospital. All India Institute of Medical Sciences, New Delhi-110029, India
,
JOSEPH DOMINIQUE
Department of Medical Oncology, Institute Rotary Cancer Hospital. All India Institute of Medical Sciences, New Delhi-110029, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
28 March 2022

© 2004. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Indian Council of Medical Research. New Delhi Bien¬nial Report 1989.
  • 2 Harriers Mark and Gore M. Chenmotherapy for epi¬thelial ovarian cancer - treatment at first diagnosis. Lancet Oncol 2002;3:529-536, 537-545 (Part I & II).
  • 3 Covens AL. A critique of surgical cytoreduction in ad¬vanced ovarian cancer. Gynecol Oncol 2000;78:269-274.
  • 4 McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophos-phamide and ‘cisplatin compared with paclitaxel and cisplatin in patients with stage III & IV ovarian can¬cer. NEJM 1996;334:1-6
  • 5 Piccart MJ, Bertelsen K, James K, et al. Randomized Intergroup Trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : Three year results. JNCI 2000;92:699-708
  • 6 Miller AB, Hoogstraten B, Staquet M and Winkler A. Reporting the results of cancer treatment. Cancer 47:207-11,1981.
  • 7 Cannistra SA Cancer of the ovary . New Eng J Med 329,1550-58.1993.
  • 8 Nejit JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92
  • 9 Nelson BE, Rosenfield AT and Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of op-timal cytoreduction in epithelial ovarian carcinoma. Jn Clin Oncol 1993;11:166-72.
  • 10 Meyer JI, Kennedy AW, Ayoub A and Zepp RC. Ovarian carcinoma : value of CT in predicting success of debulking surgery. Am J Roentgen 1995;165:875-878
  • 11 Van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. NEJM. 1995;332:629-634.
  • 12 Schwartz PE, Rutherford TJ, Chambers JT et al. Neoadjuvant chemotherapy for advanced ovarian cancer : Long term survival Gyneco Oncol 1999;72:93-99.
  • 13 Vergote IB, de Wever I, decloedt J, Tjalma W, et al. Neoadjuvant chemotherapy versus primary debulking sur-gery in advanced ovarian cancer. Sem Oncol 2000; 27(suppl. 7):31-36.